MG
ARQT icon

Mather Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Mather Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-190
Closed -$3.58K – 705
2025
Q3 		$3.58K Buy
+190
New +$3K ﹤0.01% 1460
2025
Q2 		– Sell
-190
Closed -$2.97K – 676
2025
Q1 		$2.97K Buy
+190
New +$2.68K ﹤0.01% 1507
2024
Q3 		– Sell
-190
Closed -$1.88K – 1744
2024
Q2 		$1.88K Hold
190
– – ﹤0.01% 1902
2024
Q1 		$614 Buy
+190
New +$1.42K ﹤0.01% 1668

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mather Group's ARQT Position: Q4 2025 in Review

Mather Group sold out of Arcutis Biotherapeutics (ARQT) in Q4 2025, closing a stake of 190 shares — an estimated $3.58K sold.

Mather Group first reported a position in ARQT in Q1 2024 and held it in 4 quarters. The position peaked at $3.58K in Q3 2025. 283 funds tracked by Wall St. Rank hold ARQT as of Q4 2025.

  • Mather Group reported no remaining Arcutis Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Mather Group sold 190 Arcutis Biotherapeutics shares in Q4 2025, an estimated $3.58K.
  • Mather Group first reported a position in Arcutis Biotherapeutics in Q1 2024 and held it in 4 quarters.
  • Mather Group's Arcutis Biotherapeutics position peaked at $3.58K in Q3 2025.
  • 283 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2025.

Based on Mather Group's 13F filing for Q4 2025, filed 13 Jan 2026.